This article covers the specific requirements under 21 CFR Part 820 Subpart C, the design history file (DHF), common audit findings, and how the QMSR update aligns design control requirements with ISO 13485.

What are design controls and who must follow them?

Design controls apply to all manufacturers of Class II and Class III medical devices, and to Class I devices that are automated with software or are implantable. The FDA codified design control requirements in 21 CFR Part 820.30 when it issued the original Quality System Regulation in 1996. The QMSR, which became effective February 2, 2026, retains design control requirements and aligns them more closely with ISO 13485 Section 7.3.

The purpose of design controls is to establish a defined, documented, and verifiable process for converting user needs into device specifications and to confirm through objective testing that the final device meets those specifications.

The design control sequence under 21 CFR Part 820.30

Design and development planning (§820.30(b))

Every design project must begin with a documented plan. The plan identifies the design stages, the responsibilities assigned to each stage, and the interfaces between different development teams. The plan must be updated as the project evolves.

Design input (§820.30(c))

Design inputs are the physical and performance requirements for the device derived from the intended use and user needs. They must be documented, reviewed for adequacy, and approved by a designated individual.

The most common audit finding in design inputs is incomplete or ambiguous requirements. An input that states the device must be "easy to use" is not a design input. A measurable, verifiable requirement, such as a force threshold for actuation or a specific display resolution, is a design input.

Design output (§820.30(d))

Design outputs are the documents that define the finished device: drawings, specifications, procedures, and software code. Outputs must meet design inputs, and the connection between each output and its corresponding input must be traceable.

Design review (§820.30(e))

At each major design stage, a formal documented review must occur. The review includes at least one individual who does not have direct responsibility for the design stage being reviewed. Results, including follow-up actions, must be documented.

Design verification (§820.30(f))

Verification confirms that design outputs meet design inputs. It answers the question: did we build the device we designed? Verification methods include testing, inspection, analysis, and demonstration. Each verification activity must be documented with results, dates, and the individuals who performed and approved the testing.

Design validation (§820.30(g))

Validation confirms that the finished device meets user needs and intended uses. Where practical, validation must be performed on initial production units. Validation answers the question: does the device we built actually do what users need?

Software validation under FDA's Computer System Assurance (CSA) guidance applies to software that forms part of a device or controls a device.

Design transfer (§820.30(h))

Design transfer ensures that the device design is translated into production specifications that allow consistent manufacturing. Transfer procedures must confirm that production processes can produce a device that meets specifications.

Design changes (§820.30(i))

Any change to the design after initial approval must be identified, documented, reviewed, and approved before implementation. Changes that could affect the device's safety or effectiveness require an assessment of whether a new 510(k) or PMA supplement is needed.

Design history file (§820.30(j))

The design history file is the complete record of the design and development process. It does not need to be a single document, but it must contain or reference all records needed to demonstrate that the design was developed in accordance with the approved design plan.

Common FDA audit findings in design controls

The FDA's inspection data consistently shows design controls as one of the top observation categories for medical device manufacturers. The most frequently cited specific findings include:

Traceability gaps. Design inputs are not linked to corresponding design outputs, verification tests, or validation activities. Without traceability, there is no documented confirmation that every requirement was addressed. A design traceability matrix (DTM) or requirements traceability matrix (RTM) resolves this.

Validation using prototype devices. FDA requires that validation be performed using initial production units or their equivalent. Companies that validate using hand-built prototypes or pre-production samples and then change the manufacturing process before commercial production have a validation gap.

Incomplete design reviews. Reviews that lack the documented participation of a qualified independent reviewer, or reviews where action items are not tracked to closure, do not meet §820.30(e).

Design inputs that cannot be verified. Inputs must be stated in measurable terms. Qualitative inputs like "durable," "lightweight," or "user-friendly" cannot be verified through testing. FDA cites these as inadequate design inputs.

Design change control gaps. Post-approval changes that were implemented without documentation or without a risk assessment of their impact on safety and effectiveness represent some of the most serious design control violations. These can result in the device being distributed in an unapproved configuration.

Missing or incomplete DHF records. A design history file that cannot be located, that is incomplete, or that contains records not signed and dated by the responsible individuals fails to satisfy §820.30(j).

How QMSR changes design control requirements

The FDA's Quality Management System Regulation, effective February 2, 2026, incorporated by reference ISO 13485:2016, including Section 7.3 on design and development. The QMSR retains the substantive design control requirements from 21 CFR Part 820.30 while harmonizing the terminology and structure with ISO 13485.

Key changes quality teams should note:

• The QMSR uses the term “design and development” rather than “design controls,” aligning with ISO 13485 language
• Risk management under ISO 14971 is now explicitly integrated into the design and development process, rather than being treated as a separate activity
• The QMSR requires documented design and development inputs to include applicable regulatory requirements, making it explicit that regulatory research is part of the input process
• Transfer of design to manufacturing is now referenced in the context of documented procedures, consistent with ISO 13485 Section 7.3.7

Companies already operating under ISO 13485 certification found that their existing design control procedures required relatively minor updates to comply with the QMSR. Companies operating only under the original QSR faced more substantial documentation and process updates.

Managing design controls in a QMS platform

Design controls generate a large volume of interconnected records across a long development timeline. Managing those records manually in spreadsheets or shared drives creates traceability risks and makes it difficult to demonstrate a complete DHF during an inspection.

Cloudtheapp's QMS platform includes a Design Controls application that manages the full design and development lifecycle, from design plans and input requirements through verification, validation, design reviews, change control, and DHF compilation. Each record links to related records, creating automated traceability across the development process.

The platform's design change control workflow routes change requests through configurable approval steps and triggers a risk assessment for changes that affect safety or effectiveness, directly addressing the most common design control audit finding.

For medical device manufacturers preparing for an initial FDA inspection or addressing design control observations from a prior cycle, Cloudtheapp offers a live demo showing how the platform manages design and development documentation: https://www.cloudtheapp.com/demo/

See also: How to write a design history file that passes FDA review

Key takeaways

Design controls under 21 CFR Part 820 require a documented, traceable, and verifiable development process for every medical device. The most common audit findings, traceability gaps, invalid validation, and incomplete design reviews, all reflect the same underlying issue: the design process was not planned and documented as a controlled system from the start.

The QMSR update aligns FDA's design control requirements with ISO 13485 Section 7.3 and explicitly integrates risk management throughout the design process. Companies that maintain a complete design history file with traceable links from user needs through validated device performance have a strong foundation for both FDA inspections and ISO 13485 audits.

This post created by and appeared first on Cloudtheapp

A well-constructed DHF tells a coherent story: here is what the device was intended to do, here is how design requirements were established from those intentions, here is how the design was verified to meet its requirements, and here is how it was validated to meet user needs in actual use conditions. A poorly constructed DHF — one with missing records, broken traceability between requirements and verification results, or undefined design controls — tells a very different story, one that tends to generate multiple Form 483 observations and occasionally warning letters.

This guide covers what must go into a DHF, how to structure it, and the most common mistakes that lead FDA reviewers to question whether a company’s design process was genuinely controlled.

What FDA requires in a DHF

21 CFR 820.30(j) states that each manufacturer must establish and maintain a DHF for each type of device. The DHF must contain or reference the records necessary to demonstrate that the design was developed in accordance with the approved design plan and the requirements of the design controls regulation.

The QMSR, which aligns FDA requirements more closely with ISO 13485:2016, reinforces these requirements and adds explicit expectations around risk management integration throughout the design process. A DHF that satisfies current FDA expectations covers these core areas:

• Design and development planning records
• Design input records (user needs, intended use, requirements)
• Design output records (specifications, drawings, software documentation)
• Design review records
• Design verification records
• Design validation records
• Design transfer records
• Design change records
• Risk management file records (per ISO 14971)

Each of these categories represents a phase of the design process, and they must be traceable to each other. An FDA investigator should be able to pick up any design output and trace it back to the design input that generated it, and forward to the verification test that confirmed it was met.

DHF vs. Device Master Record vs. Device History Record

The DHF is frequently confused with two related regulatory concepts. Understanding the distinction matters because FDA treats them as separate records with separate purposes.

The DHF contains the evidence of the design process: the work done to design the device. The Device Master Record (DMR) contains the specifications and procedures needed to manufacture the device: drawings, manufacturing specifications, quality plans, and labeling. The Device History Record (DHR) contains the production records for each manufactured batch or unit: what was made, when, by whom, and whether it met specifications.

These three records form a connected triad. The DHF establishes that the design is sound. The DMR defines how to build it. The DHR proves that it was built correctly. For a 510(k) submission, FDA focuses on the DHF. During a manufacturing inspection, investigators examine all three.

Structuring the DHF for FDA review

There is no single format FDA mandates for the DHF, but the structure should make traceability easy to demonstrate. A DHF that requires an investigator to search through five separate filing locations to connect a design requirement to its verification evidence is a DHF that creates problems during inspections. The best-structured DHFs are organized either chronologically by design phase or by section, with a clear index and cross-referencing between records.

Design and development planning

The DHF should begin with the design and development plan, a document that establishes the overall approach to the design project: what is being designed, who is responsible for each activity, what the project milestones are, and how design reviews will be conducted. The plan does not need to predict every activity in advance, but it should be updated as the design evolves and reviewed during formal design reviews.

Design inputs

Design inputs are the requirements the device must meet. They come from multiple sources: clinical and user needs, applicable standards, regulatory requirements, business requirements, and risk analysis. FDA expects design inputs to be documented, reviewed, and approved by qualified personnel before design work begins in earnest.

The most common design input failure is vagueness. A design input that states “the device should be easy to use” is not a requirement that can be verified. A design input that states “the device must be operated with one hand by a user wearing standard surgical gloves with a grip force not exceeding 15 Newtons” is verifiable. FDA investigators who find design inputs written in broad, unverifiable language consistently question whether the design process was genuinely controlled.

Design outputs

Design outputs are the results of design work: engineering drawings, material specifications, software design documents, labeling specifications, and manufacturing instructions. Each design output must trace to one or more design inputs, and the DHF must make this traceability visible. A design traceability matrix, linking each design input to the outputs that satisfy it and the verification tests that confirm they do, is the most efficient way to demonstrate this to an FDA reviewer.

Design reviews

Formal design reviews must be conducted at appropriate stages of the design process. The DHF must contain records of each review: who attended, what was reviewed, what questions or issues were raised, and how those issues were resolved. Design reviews that are documented only as a brief sign-off with no record of the issues discussed do not satisfy FDA’s expectations for a meaningful review process.

Design verification

Design verification confirms that design outputs meet design inputs. Verification is typically conducted through testing, analysis, inspection, or comparison to similar proven designs. Each verification activity must be documented with the verification method, the acceptance criteria, the results, and a conclusion as to whether the design input was met.

A critical point: verification confirms that you built the device to specification. It does not confirm that you built the right device. That is what validation does.

Design validation

Design validation confirms that the device meets user needs and intended uses under actual or simulated use conditions. Validation must be performed on production-equivalent units (not early prototypes), and it must address the full range of users and use environments identified in the design inputs.

For devices involving human use, validation typically includes usability testing conducted in accordance with FDA’s human factors guidance. The validation must be explicitly linked to the design inputs established at the beginning of the design process. An FDA reviewer should be able to see a direct connection between the user needs captured in design inputs and the validation test protocols designed to confirm that those needs are met.

Design transfer

Design transfer is the process of translating the design into production. The DHF must contain evidence that the design was formally transferred to manufacturing, that production processes are capable of producing devices that meet design specifications, and that the Device Master Record was established and reviewed before production began.

Design changes

Every change made to the device design after the initial design transfer must be documented in the DHF through the design change control process. The change record must include the reason for the change, the potential impact on the device’s safety, effectiveness, or regulatory status, the verification and/or validation performed to confirm the change does not create new risks, and the approval of qualified personnel.

Design changes with uncontrolled documentation are among the most frequently cited DHF deficiencies in FDA inspections. When a device undergoes multiple design iterations over its commercial life but the DHF is not updated to reflect those changes, investigators cannot determine whether the device being manufactured is actually the device that was validated.

Risk management integration

Under the QMSR and ISO 13485:2016, risk management is expected to be integrated throughout the design process, not performed as a standalone document at the end. The DHF should contain or reference the risk management file (per ISO 14971), and risk assessment results should be traceable to design inputs, design outputs, and verification/validation activities. The risk register maintained during design development must reflect how identified hazards were addressed through design changes, protective measures, or labeling.

Common DHF failures that generate FDA citations

The patterns that lead to DHF-related observations are consistent across FDA inspection reports and warning letters.

Missing traceability. A DHF where design inputs, outputs, and verification records exist as separate documents with no connecting links fails to demonstrate a controlled design process. The investigator cannot confirm that every design input was addressed by a design output and verified.

Inadequate design inputs. Vague or unverifiable design inputs are a foundational problem because everything downstream relies on them. If the requirements are not specific and measurable, verification cannot confirm they were met, and validation cannot confirm the device meets user needs.

Incomplete design change records. Device modifications made during development or post-market without corresponding design change records create a DHF that does not reflect the actual device. This is particularly problematic for software-containing devices where firmware updates may not have triggered formal change control.

Validation on non-representative units. Performing design validation on pre-production prototypes that differ materially from the production device does not satisfy FDA’s requirement that validation be performed on production-equivalent units.

No connection between risk management and design decisions. A risk management file that exists as a separate document with no visible influence on design inputs, design changes, or validation scope does not demonstrate that risk management was genuinely integrated into the design process.

How Cloudtheapp supports design history file management

Managing a DHF across a multi-year development program, with multiple engineering disciplines, iterative design changes, and evolving regulatory requirements, is genuinely difficult with paper-based or disconnected systems. When verification test results live in one system, design change records in another, and the risk management file in a third, traceability becomes a manual effort that creates inconsistency and audit risk.

Cloudtheapp’s design controls module links design inputs, design outputs, verification records, validation protocols, and design change records within a single quality management environment. The traceability matrix is generated automatically from the linked records, so quality teams spend less time assembling evidence packages and more time doing engineering work. The audit trail captures every record creation, revision, and approval, giving FDA reviewers the complete document history they expect to see.

With 60+ applications covering the full quality and compliance lifecycle for medical device, pharma, and biotech companies, Cloudtheapp supports design control programs from initial product concept through post-market design changes. Schedule a demo to see how the design controls and DHF management features work in practice.

Conclusion

A DHF that passes FDA review is not a collection of documents assembled at the end of development. It is a living record built throughout the design process, where each phase generates documented evidence that is linked to the phases before and after it. The traceability between design inputs, design outputs, verification, and validation is what gives an investigator confidence that the design process was genuinely controlled. Organizations that build traceability into their design process from the first requirements workshop tend to produce DHFs that hold up under scrutiny. Those that try to reconstruct traceability after the device is already in production typically find gaps that are difficult to close without repeating development work.

This post created by and appeared first on Cloudtheapp

Design control is the set of documented procedures, reviews, and records that govern how a medical device is designed, developed, and transferred to manufacturing. It exists because the FDA determined — after a series of device failures in the 1980s tied directly to design deficiencies — that many safety problems could be prevented if manufacturers followed a structured development process rather than designing ad hoc and testing late.

The original requirement appeared in 21 CFR Part 820.30, the Design Controls section of the Quality System Regulation (QSR), which took effect in 1996. On February 2, 2026, the FDA's Quality Management System Regulation (QMSR) replaced the QSR, aligning U.S. device requirements with ISO 13485:2016. Under the QMSR, design control requirements now map to ISO 13485 Clause 7.3 (Design and Development) rather than the prescriptive text of 820.30.

The substance of what FDA expects from design control programs has not changed significantly. The structure for demonstrating compliance has.

Who Must Follow Design Control Requirements

Under the old QSR's 820.30, design control applied to Class II and Class III devices and certain Class I devices. The QMSR and ISO 13485:2016 take a risk-based approach: design control requirements apply to any medical device where the design and development process could affect product safety, performance, or regulatory compliance.

In practice, this means most manufacturers of finished devices need documented design controls. Contract manufacturers who build to a customer-supplied design may be exempt from design control requirements for that specific product, but they must document the determination. The exemption is not assumed.

The Eight Elements of Design Control

Whether you are working under the old 820.30 or the current QMSR and ISO 13485:2016, the core elements of a design control system remain consistent.

Design and Development Planning requires a documented plan that identifies the activities required to complete the design, assigns responsibilities, and accounts for how the design interfaces with other products or systems. The plan must be updated as the design evolves. A static plan written at project kickoff and never revised is a documentation gap that FDA investigators note consistently.

Design Inputs are the documented requirements the device must meet. These include intended use, user needs, performance specifications, safety requirements, applicable standards, and regulatory requirements. Poorly defined inputs are the upstream cause of most design verification failures. If the inputs do not capture what the device actually needs to do, verification testing that confirms conformance to those inputs proves less than it appears to.

Design Outputs are the translated results of the design process: drawings, specifications, procedures, and software code. Each output must reference the input it satisfies, which is the foundation of design traceability. Under ISO 13485 Clause 7.3.4, design outputs must be in a form that allows verification against design inputs before release.

Design Review is a formal, documented examination at defined stages of the design process. It must include at least one individual who is not directly responsible for the design being reviewed. Design reviews evaluate whether the design meets its inputs, identify problems, and drive resolution before the project advances. Reviews that happen but are not documented — or that are documented as "no issues identified" without supporting records — generate audit findings during FDA inspections.

Design Verification confirms that the design output meets the design input. This is the "did we build it right" question. Verification typically involves testing, analysis, inspection, or comparison to a proven design. The verification protocol defines what will be tested, acceptance criteria, and sample sizes. When verification fails, the finding should feed back into the risk register and trigger a design change process.

Design Validation confirms that the finished device meets user needs and intended uses under actual or simulated use conditions. This is the "did we build the right thing" question. Validation must be performed on production-representative units. Validation on engineering prototypes does not satisfy the requirement. Under ISO 13485 Clause 7.3.6, software used in medical devices requires validation appropriate to its intended use and safety classification.

Design Transfer documents the process for moving the validated design into production. Transfer activities confirm that the production process can consistently produce a device that meets the design specifications. Transfer records connect the design outputs to the production documentation — drawings, work instructions, inspection criteria, and process parameters.

Design Changes require documented procedures for reviewing, approving, and implementing any change after design freeze. Under ISO 13485 Clause 7.3.9, changes must be evaluated for their effect on the complete device and on previously completed verification and validation activities. A change that affects a previously validated interface or safety-related function requires re-validation of the affected elements, not just re-testing.

What Changed Under FDA QMSR

The QMSR, effective February 2, 2026, incorporated ISO 13485:2016 by reference. This means FDA inspectors now evaluate design control compliance against ISO 13485 Clause 7.3 language rather than the specific text of 820.30.

Several practical differences follow from this shift.

The old 820.30 required a Design History File (DHF) — a compilation of records that describes the design history of a finished device. ISO 13485 Clause 7.3 does not use the term DHF, but FDA's QMSR final rule confirmed that FDA-specific requirements, including the DHF obligation, are maintained through supplemental requirements in the regulation. Manufacturers still need to maintain a DHF.

ISO 13485 Clause 7.3 introduces an explicit requirement for documented design and development inputs that include applicable regulatory requirements — a consideration for devices that need to comply with EU MDR, Canada's CMDR, or other international frameworks alongside U.S. requirements. For companies selling into multiple markets, design inputs that explicitly map to each applicable regulation simplify market-specific submission documentation.

The QMSR also strengthened the connection between design control and risk management. Under QMSR, ISO 14971 risk management outputs must be integrated into the design control process throughout development — not treated as a separate activity completed before design freeze. Design reviews must consider risk management outputs. Verification and validation activities must cover safety-critical functions identified in the risk analysis.

FDA Inspection Patterns for Design Controls

Design controls ranked as the second most frequently cited area in FDA device inspections in 2025, according to Hogan Lovells' September 2025 analysis of inspection trends. CAPA ranked first, and the two are closely connected: unresolved design control gaps frequently generate CAPAs, and CAPA investigations often surface design control deficiencies that were not previously documented.

The patterns FDA investigators find most often in design control programs:

Traceability gaps between design inputs and outputs are the single most common finding. Companies produce verification test reports but cannot show which input requirement each test was designed to verify. The traceability matrix either does not exist or was built after the fact and does not reflect the actual testing sequence.

Incomplete Design History Files are cited regularly, particularly in companies that manage design documentation across multiple systems — a PLM tool, a shared drive, and a paper archive. When an investigator requests the DHF and receives a partial compilation, the response "the rest is in the other system" is not sufficient. The DHF must be a coherent, accessible compilation.

Design changes processed outside the formal change control procedure appear in inspection records when companies make field corrections, software patches, or label changes without running those changes through the design control process. Under QMSR, any change to a previously validated design element requires documented evaluation and, where the change affects validated performance, re-validation.

Validation on non-representative units continues to be cited. Companies run final validation testing on hand-built or pre-production units and do not repeat or bracket the testing once manufacturing processes are finalized.

The Design History File: What Must Be in It

The DHF is not a single document. It is a compilation of records that, taken together, tells the complete story of how the device was designed and confirmed to meet its requirements.

A complete DHF includes the design and development plan, design input specifications, design output documentation, design review records, verification protocols and results, validation protocols and results, design transfer records, and all design change records from initial design through product release. Risk management records — per ISO 14971 — should also be referenced or included.

For companies managing DHFs in paper or disconnected electronic systems, the effort required to compile and present the DHF during an inspection is significant. The DHF must be produced quickly when requested. A two-day delay in assembling records creates its own impression during an inspection, separate from the content of the records themselves.

Managing Design Controls in an Electronic QMS

Design control in an electronic QMS connects planning documents, input specifications, output records, review sign-offs, verification and validation results, and change requests in a single traceable system. When a design input changes, the linked verification records receive an automatic notification. When a design change is submitted, the system identifies every downstream document that references the changed element.

This is the difference between traceability that exists as a spreadsheet maintained by one engineer and traceability that the system enforces by structure. During an FDA inspection, the ability to pull a complete, time-stamped, electronically signed DHF in minutes — rather than hours — directly affects how the inspection proceeds.

Cloudtheapp's Design Controls application connects inputs, outputs, reviews, and change management into a single workflow with full audit trail. Verification and validation records link directly to the design inputs they address. Request a demo at cloudtheapp.com/demo/ to see how the system handles DHF compilation and design change traceability.

The Inspection Question You Want to Be Ready For

FDA investigators ask one question in almost every device inspection that involves design controls: "Can you show me the traceability from your design inputs to your verification testing?"

Companies that answer this by opening a spreadsheet and scrolling through rows are spending inspection time explaining gaps. Companies that answer it by opening a QMS and pulling a linked traceability matrix in 30 seconds are moving on to the next question.

The design control requirement has not changed materially under QMSR. What the QMSR changed is the framework language and the explicit integration of risk management throughout the design process. For companies already running a mature ISO 13485 design control program, the transition to QMSR compliance is largely administrative. For companies that built their design control system around the specific text of 820.30 and never updated it to align with ISO 13485, there are substantive gaps to address before the next FDA Form 483 arrives.

This post created by and appeared first on Cloudtheapp

A practical guide to 510(k) QMS requirements for medical device startups — covering design controls, DHF, risk management, CAPA, and how QMSR 2026 changes what FDA expects before clearance.

What QMS Does a Medical Device Startup Need for 510(k)?

If you are building a medical device and targeting the 510(k) pathway, your quality management system is not an afterthought you stand up after clearance. It is part of the evidence that gets you there.

The FDA evaluates your 510(k) submission for substantial equivalence to a predicate device, but your QMS sits directly behind that submission. Design controls documentation, risk analysis records, verification and validation test protocols, and your Design History File all come from the same QMS you build before you submit.

Startups that delay QMS implementation until post-clearance consistently spend more time and money correcting gaps than they would have spent building it right from day one. This guide breaks down exactly what 510(k) QMS requirements apply to medical device startups, what FDA inspectors look for, and how to structure your QMS for clearance without overbuilding it.

What Is a 510(k) and Why Does Your QMS Matter for It?

A 510(k) Submission is a premarket notification submitted to the FDA under Section 510(k) of the Federal Food, Drug, and Cosmetic Act. It applies primarily to Class II medical devices and requires the manufacturer to demonstrate that the new device is substantially equivalent to a predicate device already legally on the U.S. market.

Clearance does not equal approval. FDA grants clearance based on substantial equivalence, meaning your device performs similarly to the predicate in intended use, technological characteristics, and safety profile. But the documentation that supports substantial equivalence, specifically your performance testing, risk analysis, and design records, all come from your QMS.

Beyond the submission itself, FDA can inspect your facilities after clearance or at any point during commercialization. A QMS that cannot withstand inspection is a business risk even after you clear 510(k).

Does FDA Require a Full QMS Before a 510(k) Submission?

This is one of the most common questions medical device startups ask. The direct answer: no, FDA does not require your full Quality Management System Regulation (QMSR) QMS to be operational before you submit a 510(k). However, FDA does require design controls to be in place and documented during the development process.

Design controls are not retroactive. You cannot develop your device, generate your test data, and then write your design controls documentation afterward. The controls must be in place during design and development, which means your QMS framework for design controls must exist before you begin those activities.

The practical approach for pre-production companies is to implement the QMS elements that govern design and development first, then build out the full QMS as you move toward manufacturing and commercialization. This approach satisfies 510(k) QMS requirements without requiring you to build a complete post-market QMS on day one.

The practical implication: start your QMS at the beginning of product development, not at the end.

The Core 510(k) QMS Requirements Every Startup Must Meet

The QMSR, effective February 2, 2026, incorporates ISO 13485:2016 by reference and governs all quality management system requirements for medical device manufacturers in the United States. Under QMSR and ISO 13485, the following QMS elements are directly relevant to 510(k) preparation.

Design Controls

Design controls are the most critical 510(k) QMS requirement. They are required under ISO 13485 Section 7.3 and were previously codified under 21 CFR Part 820.30. Under the 2026 QMSR, they remain a mandatory quality system element.

Design controls require you to define and document your design and development process through these stages:

Design planning: Define who is responsible for each design phase, what the inputs and outputs are, and what verification and validation activities are required.

Design inputs: Document the functional, performance, safety, and regulatory requirements your device must meet. These inputs become the basis for your verification testing.

Design outputs: Document the specifications, drawings, and production procedures that result from the design process. Outputs must meet every input requirement.

Design verification: Confirm through testing or analysis that your design outputs meet your design inputs. This is the test data that appears in your 510(k) submission.

Design validation: Confirm that your finished device meets the needs of the intended user under actual or simulated use conditions.

Design transfer: Ensure the completed design translates correctly into production specifications.

Design changes: Control and document any changes to the design after the initial approval.

Without documented design controls, your 510(k) submission lacks the technical foundation FDA expects. Design control records also feed your Design History File.

Design History File

The Design History File (DHF) is the compiled record of your device's entire design and development history. It is not a single document. It is a structured collection of all design control records, including inputs, outputs, verification test results, validation records, design reviews, and any design changes.

The DHF is what an FDA inspector reviews to verify that your device was designed in accordance with your approved design plan. A missing or incomplete DHF is one of the most common reasons 510(k) submissions receive additional information requests from FDA.

Start your DHF on day one of development. Every design review meeting, every test result, every input revision must be captured in the DHF as it happens. Reconstructing a DHF after the fact is one of the most expensive quality mistakes a startup can make.

Cloudtheapp's Design Controls application manages the full DHF lifecycle in a single validated platform, from design inputs through validation records, with a complete audit trail for every document version and approval.

Risk Management

Risk management is required by ISO 14971:2019 for all medical devices. It is also referenced throughout ISO 13485:2016, making it a direct 510(k) QMS requirement under the QMSR.

Your risk management file must include a risk management plan, hazard identification, risk analysis, risk evaluation, risk controls, and a post-production risk monitoring plan. The residual risk after controls must be acceptable relative to your device's intended benefit.

Risk analysis outputs, specifically your hazard analysis and risk control measures, also appear in your 510(k) submission as part of your safety and performance data.

A Risk Register connected to your device design records keeps risk management integrated with design controls rather than managed as a separate, disconnected exercise.

Document Control

Document control is the operational foundation of your QMS. Every procedure, specification, test protocol, and record in your QMS must be version-controlled, approved, and traceable.

For a 510(k)-stage startup, document control means:

• Every SOP has an approved version with an electronic signature and revision history
• Obsolete documents are retired immediately upon the release of a new revision
• All design and test records are controlled and retrievable on demand

FDA inspectors reviewing a 510(k) submission company will ask to see the documents behind the data. If your test protocols are uncontrolled, your test results are untrustworthy in the FDA's assessment.

CAPA

Corrective and Preventive Action (CAPA) is required under ISO 13485 Section 8.5.2 and 8.5.3. Even in a pre-production startup environment, you need a functioning CAPA process.

Why does a startup need CAPA before they have products in the field? Because nonconformances happen during development. When a test fails, when a design input changes because of a user study finding, when a supplier delivers out-of-specification material, those events require documented investigation and corrective action. CAPA is the mechanism that closes those loops.

A CAPA system that cannot document Root Cause Investigation for development nonconformances is a gap FDA will find in a post-clearance inspection.

Supplier Controls

If your device incorporates purchased components, sub-assemblies, or contract manufacturing services, ISO 13485 requires supplier controls. This includes an approved supplier list, supplier qualification records, incoming inspection procedures, and a process for issuing supplier corrective action requests when a supplier delivers nonconforming material.

For 510(k)-stage startups, supplier controls are especially important for any critical components that affect device safety or performance. Your Supplier Quality Management process does not need to be complex, but it must be documented and defensible.

How QMSR 2026 Changes 510(k) QMS Requirements

The FDA's Quality Management System Regulation (QMSR) became effective on February 2, 2026, replacing the legacy Quality System Regulation (QSR) under 21 CFR Part 820. The QMSR incorporates ISO 13485:2016 by reference, meaning FDA now enforces the full ISO 13485 standard as part of its regulatory framework.

For medical device startups pursuing 510(k), this change has three key implications.

ISO 13485 is now the U.S. standard. Companies previously operating under the QSR framework must now align with ISO 13485 requirements. For startups building a QMS from scratch, this means building to ISO 13485 from day one rather than retrofitting later.

Management responsibility language is stronger. QMSR increases the accountability requirements for senior leadership in maintaining an effective QMS. Quality objectives, management review, and resource allocation requirements are now explicitly tied to ISO 13485 language.

International alignment is complete. If your startup plans to pursue CE marking or other international regulatory clearances, a QMSR-compliant QMS that follows ISO 13485 satisfies both U.S. and international requirements simultaneously.

For more detail on the QMSR transition, see FDA QMSR 2026: The Complete Guide to the Quality Management System Regulation.

Common 510(k) QMS Mistakes Medical Device Startups Make

Startups pursuing 510(k) clearance consistently encounter the same quality system failures. Knowing these mistakes before you encounter them saves months of remediation work.

Starting the QMS too late. The most common and most costly mistake. Design controls documentation must exist from the beginning of development. Any test data generated without active design controls in place is essentially uncontrolled, and FDA will treat it that way.

Separating risk management from design controls. Risk management and design controls feed each other. Your hazard analysis informs your design inputs. Your risk controls inform your design outputs. When these are managed in separate systems with no connection between them, gaps appear in both.

Building a paper QMS. A QMS managed in binders, shared drives, and email threads cannot scale to commercialization. FDA Form 483 observations related to document control are the most consistently cited quality system finding across device inspections. Paper systems fail document control requirements.

Reconstructing the DHF after development. Many startups develop their device informally and then write their DHF documentation after the fact to prepare for submission. This approach creates audit trail gaps and is a significant inspection risk.

Treating CAPA as a post-market activity. CAPA is required during development. Every design failure, test nonconformance, and supplier deviation generates a CAPA record. A startup with zero CAPA records at submission is telling FDA they never encountered a nonconformance during development, which is not credible.

How to Build a 510(k)-Ready QMS Without Slowing Down Development

The goal is a QMS that is rigorous enough to satisfy 510(k) QMS requirements without creating administrative overhead that delays your device timeline.

Phase 1, before design begins: Establish document control, create your quality manual, define your design control procedure, and set up your risk management framework. These three elements must exist before any design activity begins.

Phase 2, during design and development: Execute design controls in real time. Create design inputs, document every design review, generate verification and validation test protocols before testing begins, and record results as they happen. Build your DHF incrementally, not retrospectively.

Phase 3, before submission: Complete your risk management file, finalize your DHF, confirm all design verification and validation records are complete, and run an internal audit against your 510(k) QMS requirements. Identify and close gaps before submission.

Phase 4, post-clearance: Build out the remaining QMS elements required for commercialization: production controls, complaint handling, post-market surveillance, and full CAPA system expansion.

Cloudtheapp's eQMS platform is built for exactly this phased approach. Medical device startups can activate the Design Controls, Document Control, Risk Management, and CAPA applications from day one, then expand to the full suite as the company scales toward production. The platform is validated to FDA QMSR and ISO 13485:2016, so every record you generate from day one is part of a defensible, audit-ready quality system.

For a broader look at QMS infrastructure for device startups, see QMS for Medical Device Startups: Building Compliance Infrastructure from Day One.

Conclusion

510(k) QMS requirements are not a compliance checkbox you satisfy at the end of development. Design controls, risk management, document control, and CAPA are the infrastructure that makes your submission credible and your post-clearance operations defensible.

Startups that build their QMS from day one spend less time in remediation, produce stronger submissions, and reach commercialization faster than those that bolt on compliance infrastructure at the end.

If your team is at the beginning of this process and looking for a validated eQMS platform built for medical device startups, book a free demo of Cloudtheapp and see how quality teams configure a full 510(k)-ready QMS in weeks, not months.

This post created by and appeared first on Cloudtheapp